Investor Relations | Prelude Therapeutics

Corporate Profile

Prelude is a clinical-stage biopharmaceutical company designing and developing a pipeline of novel, orally bioavailable, small molecule therapies that target key drivers of cancer cell growth, survival and resistance.

Change

Volume

52 Week High

52 Week Low

Data as of March 23, 2023 7:54 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest News

March 15, 2023

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting Cash balance of $201.7 million as of December 31, 2022; runway remains unchanged

March 15, 2023

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in

March 1, 2023

Prelude Therapeutics To Participate in Barclays Global Healthcare Conference

WILMINGTON, Del., March 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Barclays Global Healthcare Conference in Miami, March 14 to 16, 2023.

View All

Events

Barclays Global Healthcare Conference

March 16, 2023 at 9:30 AM EDT

2023 Wells Fargo Targeted Protein Degradation Summit

February 21, 2023 at 1:00 PM EST

2023 Wells Fargo Targeted Protein Degradation Summit

February 21, 2023 at 12:00 PM EST

View All

Presentation

March 2023 Corporate Deck

Investors

Overview

Corporate Profile